Market Research Logo

Myocardial Infarction - Pipeline Review, H2 2015

Myocardial Infarction - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Myocardial Infarction - Pipeline Review, H2 2015’, provides an overview of the Myocardial Infarction’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Myocardial Infarction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Infarction and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Myocardial Infarction
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Myocardial Infarction and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Myocardial Infarction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Myocardial Infarction pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Myocardial Infarction
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Myocardial Infarction pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Myocardial Infarction Overview
Therapeutics Development
Pipeline Products for Myocardial Infarction - Overview
Pipeline Products for Myocardial Infarction - Comparative Analysis
Myocardial Infarction - Therapeutics under Development by Companies
Myocardial Infarction - Therapeutics under Investigation by Universities/Institutes
Myocardial Infarction - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Myocardial Infarction - Products under Development by Companies
Myocardial Infarction - Products under Investigation by Universities/Institutes
Myocardial Infarction - Companies Involved in Therapeutics Development
Alligator Bioscience AB
Amarantus Bioscience Holdings, Inc.
Angion Biomedica Corp.
Aprogen, Inc.
APT Therapeutics, Inc.
AstraZeneca Plc
Athersys, Inc.
Bayer AG
Bharat Biotech International Limited
BioLineRx, Ltd.
Biscayne Pharmaceuticals, Inc.
CellProthera
Celyad
ChemoCentryx, Inc.
Compugen Ltd.
CSL Limited
FibroGen, Inc.
Fina Biotech
Hadasit Medical Research Services & Development Ltd
Human Stem Cells Institute
HUYA Bioscience International, LLC
Immune Pharmaceuticals Inc.
Inbiopro Solutions Pvt. Ltd.
Juventas Therapeutics, Inc.
Laboratoires Pierre Fabre SA
Lacer, S.A.
Lee's Pharmaceutical Holdings Limited
LegoChem Biosciences, Inc
LG Life Sciences, Ltd.
Medestea Research & Production S.p.A.
Mesoblast Limited
miRagen Therapeutics, Inc.
NeuroVive Pharmaceutical AB
Omeros Corporation
Omni Bio Pharmaceutical Inc.
Otsuka Holdings Co., Ltd.
Polyphor Ltd.
Quantum Genomics SA
Recardio GmbH
Remedy Pharmaceuticals, Inc.
Serodus ASA
STELIS Biopharma Pvt. Ltd.
Stemedica Cell Technologies, Inc.
Stempeutics Research Private Limited
TaiGen Biotechnology Co., Ltd.
Targazyme, Inc.
The International Biotechnology Center (IBC) Generium
TiGenix NV
Vicore Pharma AB
Virocan Therapeutics Private Limited
Yuyu Pharma, Inc.
Zealand Pharma A/S
Zydus Cadila Healthcare Limited
Myocardial Infarction - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ADC-1004 - Drug Profile
Alda-1 - Drug Profile
Alpha-1 Antitrypsin - Drug Profile
alteplase biosimilar - Drug Profile
AMRS-001 - Drug Profile
AmVimi-007 - Drug Profile
ANG-4011 - Drug Profile
AP-102 - Drug Profile
APT-102 - Drug Profile
balixafortide - Drug Profile
Biosimilar 3 for Rheumatoid Arthritis and Acute Myocardial Infarction - Drug Profile
Biosimilar 4 for Acute Myocardial Infarction and Infertility - Drug Profile
BIS-5409 - Drug Profile
Bone Marrow Derived Mononuclear Cells for Cardiovascular Diseases - Drug Profile
burixafor - Drug Profile
C-21 - Drug Profile
C3BSGQR-3 - Drug Profile
C3BSGQR-4 - Drug Profile
CAP-1001 - Drug Profile
CAP-1002 - Drug Profile
CCX-872 - Drug Profile
cenderitide - Drug Profile
CGEN-856 - Drug Profile
CGEN-856S - Drug Profile
CIGB-500 - Drug Profile
CM-1 - Drug Profile
Cryocell - Drug Profile
CSL-112 - Drug Profile
CTX-101 - Drug Profile
CTX-201 - Drug Profile
cyclosporine - Drug Profile
danegaptide - Drug Profile
Drugs to Inhibit Alpha Myosin for Cardiovascular Disorders - Drug Profile
Drugs to Inhibit Sir2 Protein for Ischemic Stroke and Myocardial Infarction - Drug Profile
dutogliptin tartrate - Drug Profile
Ephrin A-1 for Myocardial Infarction - Drug Profile
F-573 - Drug Profile
Fc-Alpha-1 Antitrypsin - Drug Profile
FcAAT-2 - Drug Profile
FcAAT-3 - Drug Profile
FG-6874 - Drug Profile
Gemacell - Drug Profile
Gene Therapy for Acute Myocardial Infarction - Drug Profile
glyburide - Drug Profile
HBI-3802 - Drug Profile
HYPER-IL-6 - Drug Profile
IBPB-005ET - Drug Profile
ICG-001 - Drug Profile
IS-20 - Drug Profile
JI-38 - Drug Profile
JVS-100 - Drug Profile
JVS-200 - Drug Profile
KR-33028 - Drug Profile
LA-8045 - Drug Profile
LC-280126 - Drug Profile
Mesenchymal Stem Cells - Drug Profile
MGN-1374 - Drug Profile
MGN-6114 - Drug Profile
Monoclonal Antibody Conjugates to Target Mannose Receptor for Myocardial Infarction - Drug Profile
MPC-150IM - Drug Profile
MPC-25IC - Drug Profile
MTP-131 - Drug Profile
MultiStem - Drug Profile
NVP-019 - Drug Profile
Oligonucleotide for Oncology and Cardiovascular - Drug Profile
Oligonucleotides for Cardiometabolic Diseases and Renal diseases - Drug Profile
OMS-721 - Drug Profile
OPC-28326 - Drug Profile
Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - Drug Profile
Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile
Polyglactin 370 for Acute Myocardial Infarction - Drug Profile
Protein for Cardiovascular Diseases - Drug Profile
ProtheraCytes - Drug Profile
QGC-101 - Drug Profile
RBB-001 - Drug Profile
Recombinant Protein for Myocardial Infarction - Drug Profile
Recombinant Proteins to Agonize IGF-1R for Myocardial Infarction - Drug Profile
Recombinant Prourokinase - Drug Profile
remestemcel-L - Drug Profile
rivaroxaban - Drug Profile
RNAi Oligonucleotide for Myocardial Infarction - Drug Profile
RNAi Oligonucleotide for Myocardial Infarction - Drug Profile
SBL-004 - Drug Profile
SER-130 - Drug Profile
Small Molecule for Myocardial Infarction - Drug Profile
Small Molecule to Inhibit Blood Factor XIa for CAHD and Stroke - Drug Profile
Small Molecules for Myocardial Infarction and Inflammation - Drug Profile
Small Molecules to Antagonize Adenosine A2B Receptor for Asthma and Myocardial Infarction - Drug Profile
Small Molecules to Inhibit BAX for Myocardial Infarction - Drug Profile
Small Molecules to Inhibit MMP for Myocardial Infarction - Drug Profile
Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders - Drug Profile
Stem Cell Therapy for Cardiovacular Diseases - Drug Profile
Stem Cell Therapy for Myocardial Infarction - Drug Profile
Stem Cells for Acute Myocardial Infarction - Drug Profile
Stempeucel - Drug Profile
Synthetic Peptide for Cardiovascular Diseases - Drug Profile
THR-100 - Drug Profile
ticagrelor - Drug Profile
TZ-101 - Drug Profile
VN-100 - Drug Profile
ZK-001 - Drug Profile
Myocardial Infarction - Recent Pipeline Updates
Myocardial Infarction - Dormant Projects
Myocardial Infarction - Discontinued Products
Myocardial Infarction - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Myocardial Infarction, H2 2015
Number of Products under Development for Myocardial Infarction - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Investigation by Universities/Institutes, H2 2015
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Myocardial Infarction - Pipeline by Alligator Bioscience AB, H2 2015
Myocardial Infarction - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2015
Myocardial Infarction - Pipeline by Angion Biomedica Corp., H2 2015
Myocardial Infarction - Pipeline by Aprogen, Inc., H2 2015
Myocardial Infarction - Pipeline by APT Therapeutics, Inc., H2 2015
Myocardial Infarction - Pipeline by AstraZeneca Plc, H2 2015
Myocardial Infarction - Pipeline by Athersys, Inc., H2 2015
Myocardial Infarction - Pipeline by Bayer AG, H2 2015
Myocardial Infarction - Pipeline by Bharat Biotech International Limited, H2 2015
Myocardial Infarction - Pipeline by BioLineRx, Ltd., H2 2015
Myocardial Infarction - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2015
Myocardial Infarction - Pipeline by CellProthera, H2 2015
Myocardial Infarction - Pipeline by Celyad, H2 2015
Myocardial Infarction - Pipeline by ChemoCentryx, Inc., H2 2015
Myocardial Infarction - Pipeline by Compugen Ltd., H2 2015
Myocardial Infarction - Pipeline by CSL Limited, H2 2015
Myocardial Infarction - Pipeline by FibroGen, Inc., H2 2015
Myocardial Infarction - Pipeline by Fina Biotech, H2 2015
Myocardial Infarction - Pipeline by Hadasit Medical Research Services & Development Ltd, H2 2015
Myocardial Infarction - Pipeline by Human Stem Cells Institute, H2 2015
Myocardial Infarction - Pipeline by HUYA Bioscience International, LLC, H2 2015
Myocardial Infarction - Pipeline by Immune Pharmaceuticals Inc., H2 2015
Myocardial Infarction - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2015
Myocardial Infarction - Pipeline by Juventas Therapeutics, Inc., H2 2015
Myocardial Infarction - Pipeline by Laboratoires Pierre Fabre SA, H2 2015
Myocardial Infarction - Pipeline by Lacer, S.A., H2 2015
Myocardial Infarction - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2015
Myocardial Infarction - Pipeline by LegoChem Biosciences, Inc, H2 2015
Myocardial Infarction - Pipeline by LG Life Sciences, Ltd., H2 2015
Myocardial Infarction - Pipeline by Medestea Research & Production S.p.A., H2 2015
Myocardial Infarction - Pipeline by Mesoblast Limited, H2 2015
Myocardial Infarction - Pipeline by miRagen Therapeutics, Inc., H2 2015
Myocardial Infarction - Pipeline by NeuroVive Pharmaceutical AB, H2 2015
Myocardial Infarction - Pipeline by Omeros Corporation, H2 2015
Myocardial Infarction - Pipeline by Omni Bio Pharmaceutical Inc., H2 2015
Myocardial Infarction - Pipeline by Otsuka Holdings Co., Ltd., H2 2015
Myocardial Infarction - Pipeline by Polyphor Ltd., H2 2015
Myocardial Infarction - Pipeline by Quantum Genomics SA, H2 2015
Myocardial Infarction - Pipeline by Recardio GmbH, H2 2015
Myocardial Infarction - Pipeline by Remedy Pharmaceuticals, Inc., H2 2015
Myocardial Infarction - Pipeline by Serodus ASA, H2 2015
Myocardial Infarction - Pipeline by STELIS Biopharma Pvt. Ltd., H2 2015
Myocardial Infarction - Pipeline by Stemedica Cell Technologies, Inc., H2 2015
Myocardial Infarction - Pipeline by Stempeutics Research Private Limited, H2 2015
Myocardial Infarction - Pipeline by TaiGen Biotechnology Co., Ltd., H2 2015
Myocardial Infarction - Pipeline by Targazyme, Inc., H2 2015
Myocardial Infarction - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2015
Myocardial Infarction - Pipeline by TiGenix NV, H2 2015
Myocardial Infarction - Pipeline by Vicore Pharma AB, H2 2015
Myocardial Infarction - Pipeline by Virocan Therapeutics Private Limited, H2 2015
Myocardial Infarction - Pipeline by Yuyu Pharma, Inc., H2 2015
Myocardial Infarction - Pipeline by Zealand Pharma A/S, H2 2015
Myocardial Infarction - Pipeline by Zydus Cadila Healthcare Limited, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Myocardial Infarction Therapeutics - Recent Pipeline Updates, H2 2015
Myocardial Infarction - Dormant Projects, H2 2015
Myocardial Infarction - Dormant Projects (Contd..1), H2 2015
Myocardial Infarction - Dormant Projects (Contd..2), H2 2015
Myocardial Infarction - Dormant Projects (Contd..3), H2 2015
Myocardial Infarction - Dormant Projects (Contd..4), H2 2015
Myocardial Infarction - Dormant Projects (Contd..5), H2 2015
Myocardial Infarction - Dormant Projects (Contd..6), H2 2015
Myocardial Infarction - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Myocardial Infarction, H2 2015
Number of Products under Development for Myocardial Infarction - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report